10X Capital Venture III Seeks Extra 6 Months to Work on American Gene Deal

10X Capital Venture Acquisition III in a proxy filing proposes a deadline extension up to January 2025 while it works to complete a merger with American Gene Technologies. The current deadline is July 14.

The SPAC held just over $22.6 million as of June 6, according to the proxy. 10X originally raised $304.5 million in a January 2022 IPO and private placement. The SPAC lost $266.7 million from its trust due to redemptions on an extension vote in December 2022.

If the extension is approved, the sponsor will continue to receive payments from the SPAC of $37,500 per month for office space and secretarial and administrative services.

10X Capital Venture III in August last year announced a merger agreement with American Gene Technologies International at pre-money enterprise value of $500 million. At deal announcement, the transaction was expected to close in the first quarter of 2024. Read more.

Related Posts
Read More

NorthView Acquisition Files Amended Proxy on Profusa Deal

Based in Emeryville, CA, Profusa “is pioneering the next generation of personalized medicine via the development of novel tissue-integrated biosensors. Profusa’s technology addresses the human body’s response to the presence of foreign material, enabling long-term monitoring of various biochemical parameters in real-time.”